AR Findings Highlight Detailed Tumor-Profiling Study
March 7th 2014A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression.
Read More
Patients With High PD-L1 Expression in mRCC are Less Sensitive to VEGF-Targeted Drugs
February 4th 2014According to a retrospective analysis of the phase III COMPARZ trial, high tumor expression of the protein PD-L1 (programmed cell death 1 ligand 1) is independently associated with shorter overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) receiving treatment with vascular endothelial growth factor (VEGF)-targeted therapy.
Read More
Two New Drug Pairings are Active in Advanced and Refractory Urothelial Cancer, Studies Show
February 2nd 2014Investigators reported at the 2014 Genitourinary Cancers Symposium that two new combinations demonstrated activity in refractory or advanced, previously untreated urothelial carcinoma in phase II evaluations.
Read More
Increased Use of Second-Line Therapies Has Not Improved Survival in Metastatic Urothelial Cancer
February 1st 2014Survival, measured as either disease-specific survival or relative conditional survival, has not improved for patients with metastatic urothelial carcinoma despite increasing use of second-line therapies with no formal indication in this setting.
Read More
A Biomarker Development Trial of Satraplatin in Patients With mCRPC
February 1st 2014William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.
Read More
Safety of Radium-223 in mCRPC Endures in Extended Follow-up
January 31st 2014Patients with bone metastatic castration-resistant prostate cancer (CRPC) who received radium-223 dichloride (Xofigo) continued to have a low incidence of myelosuppression and no associated secondary malignancies at a 1.5-year follow-up of the pivotal phase III ALSYMPCA study that was presented at the 2014 Genitourinary Cancers Symposium.
Read More
Abiraterone and Enzalutamide for mCRPC
January 31st 2014Charles Ryan, MD, Associate Clinical Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the utility of abiraterone and enzalutamide for patients with metastatic castration-resistant prostate cancer.
Read More
The Impact of Angiotensin System Inhibitors on Outcomes in Patients with mRCC
January 31st 2014Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, discusses a trial that analyzed overall survival in patients with metastatic renal cell carcinoma who used angiotensin system inhibitors.
Read More
Benefit for Radiotherapy/ Antiandrogen Combination Reinforced by Long-Term Data
January 30th 2014Improved outcomes continued to be demonstrated with the addition of radiotherapy to oral antiandrogen therapy in men with locally advanced prostate cancer, according to an updated analysis, conducted after 11 years of observation.
Read More
Twenty Percent of Cancer Trials End Prematurely, but GU Research Not More Susceptible
January 29th 2014The premature termination of clinical trials in the oncology setting is a problem that continues to vex researchers, and results of a new study that involved more than 7500 adult cancer clinical trials suggest that the concern is justified.
Read More
Vaccine Combination Demonstrates Benefit in Metastatic Pancreatic Cancer
January 15th 2014According to the results of a phase II study, the combination of two specific anti-cancer vaccines, rather than the administration of one as monotherapy, doubles the 1-year survival probability in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
Read More
RAS Testing Before Panitumumab Use in mCRC Confirmed by Second-Line Data
January 15th 2014RAS mutations beyond KRAS exon 2 are negative predictive biomarkers for the EGFR-inhibitor panitumumab in metastatic colorectal cancer, according to an analysis of phase III, second-line data, which are consistent with previously reported data in first-line mCRC.
Read More
Capecitabine/ Temozolomide Elicits 'Extraordinary' Responses in Chemo-Resistant NETs
January 15th 2014Patients with carcinoid and pituitary NETs, who have been traditionally chemo-resistant, may obtain "extraordinary responses" with capecitabine and temozolomide (CAPTEM), according to data from an interim analysis of an ongoing phase II study.
Read More
Capecitabine as Effective as Infusional Chemotherapy in Rectal Cancer
January 15th 2014According to findings from a four-arm phase III NSABP R-04 trial, single-agent neoadjuvant capecitabine combined with radiation therapy demonstrated similar outcomes as previously established standards of care for patients with stage II or stage III rectal cancer.
Read More
Ramucirumab/Paclitaxel Combination Shows OS Benefit in Metastatic Gastric Cancer
January 15th 2014The combination of ramucirumab and paclitaxel resulted in a significant prolongation in survival and gains in quality of life when compared to paclitaxel alone for the second-line treatment of patients with metastatic gastric cancer.
Read More
Neoadjuvant Carboplatin Increases pCR Rates in TNBC
December 16th 2013Study investigators reported at the 2013 San Antonio Breast Cancer Symposium that the addition of carboplatin to standard neoadjuvant chemotherapy increased pathologic complete response (pCR) rates in patients with triple-negative breast cancer (TNBC).
Read More
Survival Not Extended by Locoregional Treatment of MBC
December 16th 2013According to the results of a prospective, randomized, controlled trial, in women with metastatic breast cancer that responds to frontline chemotherapy, locoregional treatment (LRT) of the primary tumor and axillary nodes does not produce an increase in overall survival (OS).
Read More
PIK3CA Mutation Predicts Resistance to HER2-Targeted Therapy
December 16th 2013Findings reported at the 2013 San Antonio Breast Cancer Symposium showed that PIK3CA-mutated tumors in patients with HER2-positive (HER+) breast cancer (BC) are associated with a much lower rate of pathological complete response (pCR).
Read More